About Us

The Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) is a consortium that depends on Instituto de Salud Carlos III (Ministerio de Economía y Competitividad). The main objective of CIBERDEM (Diabetes and Associated Metabolic Diseases) is to lead the investigative effort of excellence in diabetes and associated metabolic diseases, as well as to accelerate the transfer of results to clinical practice, favouring the flow of knowledge obtained in diabetes to other disciplines and vice versa.

It is formed by 30 reference groups located in 19 institutions in the consortium, including hospitals, universities and research centres of Spain, from 6 Spanish Regions. CIBERDEM works in three corporate programmes:

  • P1: Epidemiology, genetics and epigenetics of diabetes mellitus. Chronic complications and comorbidities.
  • P2: Molecular and cellular determinants of the function, lesion and protection of pancreatic islets. Regenerative medicine and advanced therapies.
  • P3: Cellular and molecular mechanisms involved in the development and progression of type 2 diabetes and identification of new therapeutic targets.